Introduction
Trigger point dry needling (TrP-DN) is an invasive treatment approach whereby a solid filament needle is inserted into a myofascial trigger point (TrP) in a muscle. 1, 2 A TrP consists of a hyperirritable spot in skeletal muscle, associated with a palpable nodule in a taut band. When compressed, TrPs may give rise to characteristic pain, tenderness, or motor dysfunction. 3 Superficial dry needling (SDN) involves inserting the needle into the skin, fascia, and muscle overlying a TrP, 4 whereas, with deep dry needling (DDN) the needle is inserted into the TrP with the aim of eliciting Local Twitch Responses (LTRs). 5 Essential for obtaining therapeutic benefit with TrP-DN, LTRs are reflex spinal cord contractions of the muscle fibers in a taut band. [6] [7] [8] Eliciting LTRs can reduce concentrations of nociceptive chemicals, such as substance P and calcitonin gene-related peptide, found in the immediate vicinity of active TrPs. 9, 10 Trigger point dry needling is commonly used in clinical practice by physiotherapists in conjunction with other physical therapy modalities. 1 In many countries, including Ireland, the United Kingdom, Canada, and Spain, TrP-DN has been recognized to fall within the scope of physiotherapy practice. 1 In fact, the term 'intramuscular manual therapy' is considered by some to be a more appropriate term for TrP-DN as this technique is closely associated with manual therapy. 2 Research is emerging supporting the use of TrP-DN for conditions such as back and neck pain, [11] [12] [13] shoulder pain, 14 and upper quadrant myofascial pain. 15 Furlan et al. 16 conducted a systematic Cochrane meta-review of randomized controlled trials investigating acupuncture and TrP-DN for back pain. Trigger point dry needling was found to be a useful adjunct to other therapies in the treatment of persons with chronic low back pain. When used to treat individuals with temporomandibular pain and dysfunction, TrP-DN can also improve pain and movement. [17] [18] [19] Non-invasive approaches, including TrP compression release and spray and stretch, are also used to treat TrPs. [20] [21] [22] [23] [24] Trigger point dry needling is an invasive technique with potential for Adverse Events (AEs).
Searches of Pubmed, Medline, and CINAHL by the authors did not find any studies investigating AEs and TrP-DN beyond the level of case study.
Evidence on the safety of needling techniques comes primarily from prospective studies investigating AEs following acupuncture. [26] [27] [28] [29] [30] [31] Results from acupuncture AE studies cannot be extrapolated and applied to TrP-DN as it differs from acupuncture in the points treated and the method and depth of needle stimulation. 27 however the majority of these could be viewed as positive such as feeling relaxed, and feeling energized. The acupuncture evidence, although useful, is not sufficient for ensuring the safety of patients undergoing TrP-DN due to the differences that exist between the two techniques. Trigger point dry needling, especially DDN, is performed with greater needle depth and involves manipulating the needle within the muscle to elicit multiple LTRs, 1 whereas, with acupuncture, the needle commonly is inserted to the depth of the acupoint and manipulated gently until a dull ache called 'deqi' is achieved. 32 The needle may then be left in situ for as long as 15-20 minutes. Furthermore, the education of acupuncturists and physiotherapists using TrP-DN is considerably different. 5 A specific study of AEs following TrP-DN was, therefore, deemed necessary. The aim of this study was to determine the incidence of AEs associated with the use of TrP-DN as practiced by a sample of physiotherapists with David G Simons Academy (DGSA) training in Ireland.
Methods Definition
For the purposes of this study, an AE was defined as 'any ill-effect, no matter how small, that is unintended and non-therapeutic'. 33 This was chosen to include mild events and events that occurred through error. 28 Based on severity, AEs were sub-classified as 'significant' or 'mild'. The definitions for 'significant' and 'mild' events were adapted from those proposed by Carnes et al. 34 In the current study, a 'mild' AE was defined as short-term and non-serious, with no change in function, whereas the term, 'significant', was chosen to represent moderate or major AEs, described by Carnes et al. 34 as medium to long-term events that are serious, distressing and may require further treatment. In the study by Carnes et al., 34 specific time frames were not included in the final definitions of mild, moderate, or major AEs. However, the general consensus (.74%) was that mild AEs lasted hours, moderate AEs lasted days and major AEs lasted weeks. These differed from the time frames discussed in a separate study considering AEs from the patient perspective. 35 In that study, a mild AE was described as lasting from a matter of hours to 2 days by different participants. Moderate AEs could last from 1-5 days and major for more than 2 days. Due to these discrepancies in the literature and the multi-factorial nature of defining an AE, 35 it was decided not to impose a strict time frame on distinguishing a mild AE from a significant one.
Ethical approval
Exemption from ethical approval was granted by the Human Research Ethics Committee of University College Dublin on 23 June 2011.
Study design
A prospective questionnaire design was used in this study to avoid recall error.
Survey forms
The questionnaire consisted of two forms, modified with permission from those used by White et al., 28 and a demographic data form. The forms were piloted by two physiotherapists for 2 weeks and subsequently, small changes were made. Form A was used to record the number of TrP-DN treatments completed monthly and any mild AEs experienced. Specific headings for recording mild events included: bruising, bleeding, pain during treatment, pain after treatment, headache, and other mild AEs. This form was completed and returned monthly to the researchers. The form used to record physiotherapists' demographic data was returned with Form A following month one.
On a separate form (Form B) participants recorded any significant AEs. This could include: needling problems (e.g. forgotten needles, pneumothorax); systemic effects (e.g. fainting, vomiting); influence on symptoms (prolonged aggravation); or other significant events. Participants were asked to record the muscle being treated when the event occurred, the technique used, any necessary medical intervention, and the outcome. Form B was returned with Form A at the end of each month.
Subjects
In the study, 183 physiotherapists who had completed TrP-DN training with the DGSA were eligible to take part. Training with the DGSA in Ireland takes 64 hours 36 and is available only to physiotherapists.
This includes a two-day course on foundations of myofascial pain and MTrP palpation. Physiotherapists then complete two, three-day TrP-DN courses. DN 1 is concerned with needling safety as well as needling techniques for the upper and lower extremities. DN 2 is completed some months later with emphasis on the muscles of the trunk spine and pelvis. This model has been used extensively in Switzerland and other European countries.
Recruitment
Eligible physiotherapists were invited by email to take part in the study by one of the authors (JM). Potential participants were advised to email the principal investigator (SB) directly if they wished to volunteer for the study. Reminder emails were sent at two and four weeks to non-respondents.
Distribution
Following recruitment, packs were mailed to participants containing: an information leaflet, contact details of the researchers, nine copies of Forms A and B, a demographic data form and nine stamped addressed envelopes. Participants were informed that each respondent would be assigned a code for reporting and only the principal investigator (SB) would have access to the codes. Confidentiality was assured and participants informed that by volunteering for the study they were giving consent for data to be used for this purpose.
Survey size
The study aimed to identify any rare AEs, meaning a sample size of greater than 10 000 treatments was necessary. 37 It was hoped to recruit a third of the 183 eligible physiotherapists (n561). Through discussion with physiotherapists, it seemed reasonable that participants would use TrP-DN 20 times per month. A time frame of 9 months was calculated as being required to record 10 000 treatments.
Analysis
Results were analyzed using Statistical Package for the Social Sciences 18 (SPSS). Descriptive statistics were used to calculate frequencies of various AEs and rates of occurrence per 100 treatments. Adverse Events were classified based on how frequently they occurred, ranging from very common (more that once in ten treatments) to very rare (less than once in 10 000 treatments) following the European Commission's (EC) recommended classification of AEs (Table 1) . 37 
Results
In the study, 183 physiotherapists were invited to take part. Of these, 51 volunteered to participate and questionnaire packs were posted to all 51. Of the 51 volunteers, 39 returned at least one Form A giving a response rate of 76.47%. Demographic data (Table 2) were provided by 35 of the 39 participants (89.74%). Of the remaining four participants, one reported forgetting Six participants reported rates of AEs per 100 treatments that were greater than 1 sd above the mean (.44.27 AEs per 100 treatments). The MannWhitney test was used to compare medians for the seven most common AEs between these six participants and the remaining 33 participants. Medians were significantly higher among the outliers for bleeding (P50.003), bruising (P50.001), and pain during treatment (P50.003). Medians were higher for the remaining AEs but were not statistically significant for pain after treatment (P50.758), aggravation (P50.154), drowsiness (P50.898), and feeling faint (P50.148).
Discussion
In this study, AEs were reported in 19.18% (n51463) of treatments using TrP-DN. Adverse Events would therefore be considered very common. 37 All AEs reported were mild and no significant AEs were reported. This implies that the estimated risk of significant AEs using Hanley's Rule of Three 38 was #0.04% (3/7629). Therefore, in this study, the estimated rate of significant AEs can be considered, at worst, rare. Although no significant AEs occurred, the results should be interpreted in light of the sample size of the current study. Studies using greater numbers of treatments are needed to determine a more accurate rate of significant AEs. When compared with similar prospective studies on acupuncture, the AE rate of 19.18% reported in this study appears high. Yamashita et al. 26 26 AEs were only reported if the practitioner or patient felt it was a problem, which may account for the low rate of AEs in their study (0.14%).
The current study used a similar methodology to White et al., 28 but that study reported a lower rate of AEs, 7%. Acupuncture and TrP-DN differ in the points treated and methods and depth of needle stimulation, and therefore are not directly comparable. It should be noted that there are many different schools of acupuncture with different treatment points and techniques. 5 The manipulation of the needle with
TrP-DN to elicit multiple LTRs 1 is distinctly different from acupuncture where the needle is normally inserted to the depth of the acupoint and manipulated gently until a dull ache called 'deqi' is achieved. 32 It is likely that compared with acupuncture, TrP-DN could lead to more local microtrauma resulting in bruising, bleeding, and pain. 41 In the current study, however, no significant AEs were reported in 7629 treatments, giving an upper risk rate for significant AEs of #0.04%. 38 This compares favorably with 0.14% in the study by White et al. 28 and 0.22% (AEs requiring further treatment) in the study by Witt et al. 30 The estimated risk of significant AEs in this study (#0.04%) is also much lower than that reported for some over-the-counter pain medications (aspirin, 18.7%; ibuprofen, 13.7%; and Paracetamol, 14.5%). 42 In the current study a large variation is seen in the rate of AEs reported per participant with figures ranging from 3.13-93.1/100 treatments with six of the 39 participants reporting particularly high rates of AEs. Among these six participants, rates of reporting of bruising (P50.003), bleeding (P50.001), and pain during treatment (P50.003) were significantly higher compared with the other 33 participants. Participants were instructed to record any bruise as an AE, but the recording forms did not state how much bleeding or what level of pain constituted an AE. The definition of an AE was printed on all forms, but it is conceivable that different participants made interpretations as to what was meant by an AE. Varied rates of reporting could also arise due to differences in needling techniques or patient cohorts. The reasons for these differences are unknown as a follow-up of participants was not part of this study's methodology. White et al. 28 carried out a follow-up of participants with high rates of reporting and found that these participants had reported slight discomfort or a single drop of blood as an AE. Similar follow-up may be beneficial in future studies on TrP-DN. The definition used in the current study was chosen to be capable of identifying mild and significant events, 33 35 Further studies may use an alternative system of reporting to account for events considered 'not adverse'. Problems can also arise due to the lack of consistency in the terms used for recording recording AEs. Calls have been made to standardize terminology. 43 This variation in terminology makes comparisons between similar studies difficult.
There are a number of limitations to the current study. No significant AEs were reported, therefore, the risk of significant AEs could only be estimated using Hanley's Rule of Three. 38 This should be interpreted with caution as it is only an estimation, and further large-scale studies are indicated. Participants may have been reluctant to report events where negligence could be inferred, as participants were potentially identifiable. Future studies should consider the benefits of anonymous reporting. Some AEs may have been wrongly attributed to TrP-DN, as participants were not asked to judge causality, thus leading to possible over-reporting of mild AEs. This study was designed as a prospective study in an effort to obtain the most accurate results. However, as forms were returned at the end of each month, it is possible that participants completed the forms retrospectively at the end of each month rather than as each event occurred, introducing the possibility of inaccurate reporting. Adverse Events can and do occur with needling therapies and when choosing a treatment approach, the risk of both mild and significant AEs must be discussed with patients. 44 Clinicians should strive to maintain safety at all times and this paper provides practitioners using TrP-DN with a means of discussing the known risks in order to obtain informed consent.
Conclusion
Almost 20% of treatments with TrP-DN by the physiotherapists in this study resulted in a mild AE. Common AEs include bruising, bleeding, and pain. No significant AEs occurred and the estimated risk of significant AE was #0.04% by Hanley's Rule of Three. 38 This must be viewed in light of the scale of the study and further large-scale studies are warranted.
